L3VLUP
ProSign in

GILD · RVMD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

GILDRVMD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • GILD
  • RVMD
010203040202120222023202420252026
Holders and value by quarter
QuarterGILDRVMD
Q3 202025 holders, $14.2bn3 holders, $388m
Q4 202027 holders, $13.4bn4 holders, $451m
Q1 202124 holders, $14.5bn5 holders, $846m
Q2 202118 holders, $14.9bn5 holders, $325m
Q3 202120 holders, $16.4bn3 holders, $133m
Q4 202120 holders, $16.8bn3 holders, $174m
Q1 202228 holders, $13.2bn3 holders, $174m
Q2 202226 holders, $13.6bn3 holders, $189m
Q3 202224 holders, $13.3bn3 holders, $206m
Q4 202232 holders, $21.1bn3 holders, $263m
Q1 202327 holders, $21.8bn5 holders, $526m
Q2 202324 holders, $20.7bn7 holders, $685m
Q3 202324 holders, $20.0bn8 holders, $766m
Q4 202322 holders, $21.5bn8 holders, $1.0bn
Q1 202430 holders, $20.3bn10 holders, $1.3bn
Q2 202428 holders, $18.5bn9 holders, $1.6bn
Q3 202429 holders, $24.2bn10 holders, $1.9bn
Q4 202428 holders, $25.9bn11 holders, $2.2bn
Q1 202533 holders, $32.0bn7 holders, $1.7bn
Q2 202527 holders, $30.9bn8 holders, $1.7bn
Q3 202523 holders, $29.4bn7 holders, $2.2bn
Q4 202525 holders, $34.3bn18 holders, $4.3bn
Q1 202625 holders, $38.5bn15 holders, $4.8bn
Q2 202626 holders, $34.2bn17 holders, $10.3bn
GILD

Gilead Sciences Inc

Holders
33
Reported value
$32.0bn
Buyers
21
Sellers
12

Breadth +9 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
RVMD

Revolution Medicines Inc

Holders
7
Reported value
$1.7bn
Buyers
5
Sellers
1

Breadth +4 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q1 2025

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only GILD (28)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Element Capital Management LLC, ExodusPoint Capital Management LP, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Point72 Asset Management LP, Renaissance Technologies LLC, and 3 more

Only RVMD (2)

Farallon Capital Management LLC, Moore Capital Management LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →